The Individualized Management With Pegasys and Ribavirin Offering Viral Eradication (IMPROVE) Trial
Phase of Trial: Phase III
Latest Information Update: 01 Feb 2017
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms IMPROVE
- Sponsors Roche
- 31 Aug 2018 Biomarkers information updated
- 17 Aug 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
- 23 Feb 2010 Planned end date changed from 1 Jul 2010 to 1 Aug 2010 as reported by ClinicalTrials.gov.